Medifast, Inc. (MED)

NYQ – Real vaqt narxi. Valyuta: USD

11.72

+0.07 (0.60%)

Bozor ochiq: Aug 12, 2026, 1:08 PM EDT

11.88

+0.23 (1.97%)

Oldingi bozordan keyin: Aug 11, 2026, 7:34 PM EDT

07.08.2026

Is MED Worth Buying as Low Valuation Meets a High-Risk Turnaround?

Medifast's low valuation and improving coach productivity offer potential, but a shrinking coach base and weak growth keep the turnaround high risk.

07.08.2026

MED Rallies 13.6% in the Past Month: Can the Momentum Keep Building?

Medifast stock gains 13.6% in a month as improving coach productivity and earnings expectations support momentum despite weaker revenue.

07.08.2026

Can MED's Trilivy Launch and Cost Cuts Drive a Q4 Profit Turnaround?

Medifast's Trilivy launch and cost cuts could support a Q4 profit turnaround, but shrinking revenue and its coach base keep risks high.

06.08.2026

Medifast: Worth A Speculative Entry As Sales Stabilize (Rating Upgrade)

Medifast, Inc. has started to report stabilizing sales through improved coach productivity, shown again in the Q2 report. Stabilized sales provide a pathway to stabilize earnings. MED targets profitability by Q4 already, but the target has to be taken with caution. Due to MED's $15.2 in net cash per share, the stock seems attractive. I estimate 44% upside to $18.8 on the condition that earnings improve near breakeven.

04.08.2026

Medifast Q2 Loss Narrower Than Expected, Coach Productivity Improves

MED tops Q2 earnings expectations despite lower sales, as rising coach productivity helps offset pressure from a shrinking coach network.

04.08.2026

Medifast, Inc. (MED) Q2 2026 Earnings Call Transcript

04.08.2026

Medifast Q2 Earnings Call Highlights

Medifast NYSE: MED reported second-quarter 2026 revenue of $76.4 million, down 27.6% from a year earlier, as its active earning coach base continued to decline amid the rapid adoption of GLP-1 medications across the traditional weight-loss category. The company posted a net loss of $3.1 million, or $0.28 per diluted share, compared with net income of $2.5 million, or $0.22 per share, in the prior-year quarter.

Videolar

No Data

There is no data to display

Press-relizlar

03.08.2026

Medifast Announces Second Quarter 2026 Financial Results

BALTIMORE--(BUSINESS WIRE)--Medifast (NYSE: MED), the health and wellness company known for its science-backed comprehensive metabolic health system, Trilivy, today reported results for the second quarter ended June 30, 2026. Second Quarter 2026 Revenue: $76.4 million, with revenue per active earning coach of $6,529 Independent active earning coaches of 11,700 Net loss of $3.1 million or $0.28 loss per diluted share ("EPS") Cash, Cash Equivalents, and Investment Securities of $169.8 million wit.

Medifast, Inc. (MED)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Medifast, Inc. (MED)

Is MED Worth Buying as Low Valuation Meets a High-Risk Turnaround?

MED Rallies 13.6% in the Past Month: Can the Momentum Keep Building?

Can MED's Trilivy Launch and Cost Cuts Drive a Q4 Profit Turnaround?

Medifast: Worth A Speculative Entry As Sales Stabilize (Rating Upgrade)

Medifast Q2 Loss Narrower Than Expected, Coach Productivity Improves

Medifast, Inc. (MED) Q2 2026 Earnings Call Transcript

Medifast Q2 Earnings Call Highlights

Videolar

No Data

Press-relizlar

Medifast Announces Second Quarter 2026 Financial Results

Is MED Worth Buying as Low Valuation Meets a High-Risk Turnaround?

MED Rallies 13.6% in the Past Month: Can the Momentum Keep Building?

Can MED's Trilivy Launch and Cost Cuts Drive a Q4 Profit Turnaround?

Medifast: Worth A Speculative Entry As Sales Stabilize (Rating Upgrade)

Medifast Q2 Loss Narrower Than Expected, Coach Productivity Improves

Medifast, Inc. (MED) Q2 2026 Earnings Call Transcript

Medifast Q2 Earnings Call Highlights

Videolar

No Data

Press-relizlar

Medifast Announces Second Quarter 2026 Financial Results

Search stocks

Medifast, Inc. (MED)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Medifast, Inc. (MED)

Is MED Worth Buying as Low Valuation Meets a High-Risk Turnaround?

MED Rallies 13.6% in the Past Month: Can the Momentum Keep Building?

Can MED's Trilivy Launch and Cost Cuts Drive a Q4 Profit Turnaround?

Medifast: Worth A Speculative Entry As Sales Stabilize (Rating Upgrade)

Medifast Q2 Loss Narrower Than Expected, Coach Productivity Improves

Medifast, Inc. (MED) Q2 2026 Earnings Call Transcript

Medifast Q2 Earnings Call Highlights

Videolar

No Data

Press-relizlar

Medifast Announces Second Quarter 2026 Financial Results

Is MED Worth Buying as Low Valuation Meets a High-Risk Turnaround?

MED Rallies 13.6% in the Past Month: Can the Momentum Keep Building?

Can MED's Trilivy Launch and Cost Cuts Drive a Q4 Profit Turnaround?

Medifast: Worth A Speculative Entry As Sales Stabilize (Rating Upgrade)

Medifast Q2 Loss Narrower Than Expected, Coach Productivity Improves

Medifast, Inc. (MED) Q2 2026 Earnings Call Transcript

Medifast Q2 Earnings Call Highlights

Videolar

No Data

Press-relizlar

Medifast Announces Second Quarter 2026 Financial Results